BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19155535)

  • 1. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
    Kelly DJ; Edgley AJ; Zhang Y; Thai K; Tan SM; Cox AJ; Advani A; Connelly KA; Whiteside CI; Gilbert RE
    Nephrol Dial Transplant; 2009 Jun; 24(6):1782-90. PubMed ID: 19155535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
    Kelly DJ; Chanty A; Gow RM; Zhang Y; Gilbert RE
    J Am Soc Nephrol; 2005 Jun; 16(6):1654-60. PubMed ID: 15843473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C β inhibition ameliorates experimental mesangial proliferative glomerulonephritis.
    Tokuyama H; Kim S; Zhang Y; Langham RG; Cox AJ; Gow RM; Kelly DJ; Gilbert RE
    Nephrology (Carlton); 2011 Sep; 16(7):649-55. PubMed ID: 21575103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
    Kelly DJ; Buck D; Cox AJ; Zhang Y; Gilbert RE
    Am J Physiol Renal Physiol; 2007 Aug; 293(2):F565-74. PubMed ID: 17522264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C-beta inhibition for diabetic kidney disease.
    Tuttle KR
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S70-4. PubMed ID: 18977550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
    Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
    Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
    Kelly DJ; Zhang Y; Hepper C; Gow RM; Jaworski K; Kemp BE; Wilkinson-Berka JL; Gilbert RE
    Diabetes; 2003 Feb; 52(2):512-8. PubMed ID: 12540629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High glucose stimulates hyaluronan production by renal interstitial fibroblasts through the protein kinase C and transforming growth factor-beta cascade.
    Takeda M; Babazono T; Nitta K; Iwamoto Y
    Metabolism; 2001 Jul; 50(7):789-94. PubMed ID: 11436183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
    Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
    Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
    Tuttle KR; Anderson PW
    Am J Kidney Dis; 2003 Sep; 42(3):456-65. PubMed ID: 12955673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats.
    Wei L; Sun D; Yin Z; Yuan Y; Hwang A; Zhang Y; Si R; Zhang R; Guo W; Cao F; Wang H
    Apoptosis; 2010 Apr; 15(4):488-98. PubMed ID: 20044781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
    Tuttle KR; McGill JB; Haney DJ; Lin TE; Anderson PW;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):631-6. PubMed ID: 17699475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
    Gilbert RE; Kim SA; Tuttle KR; Bakris GL; Toto RD; McGill JB; Haney DJ; Kelly DJ; Anderson PW
    Diabetes Care; 2007 Apr; 30(4):995-6. PubMed ID: 17229944
    [No Abstract]   [Full Text] [Related]  

  • 17. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
    Koya D; Haneda M; Nakagawa H; Isshiki K; Sato H; Maeda S; Sugimoto T; Yasuda H; Kashiwagi A; Ways DK; King GL; Kikkawa R
    FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKC inhibition and diabetic microvascular complications.
    Clarke M; Dodson PM
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice.
    Ohshiro Y; Ma RC; Yasuda Y; Hiraoka-Yamamoto J; Clermont AC; Isshiki K; Yagi K; Arikawa E; Kern TS; King GL
    Diabetes; 2006 Nov; 55(11):3112-20. PubMed ID: 17065350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study.
    Cherney DZ; Konvalinka A; Zinman B; Diamandis EP; Soosaipillai A; Reich H; Lorraine J; Lai V; Scholey JW; Miller JA
    Diabetes Care; 2009 Jan; 32(1):91-3. PubMed ID: 18945921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.